Application Seeks Marketing Approval for ADASUVE for the Rapid Treatment of Agitation in Adults with Schizophrenia or Bipolar Disorder

Coming soon to an ER near you…Nasal spray delivery of med for the emergency control of agitation in schizophrenic and bipolar patients:

About Agitation

Agitation can occur in many people suffering from major psychiatric disorders, including schizophrenia, which affects approximately 2.4 million adults in the United States, and bipolar disorder, which affects approximately 5.7 million adults in the United States. More than 90% of these people will experience agitation in their lifetime. Agitation generally escalates over a short period of time with patients initially feeling uncomfortable, tense and restless. As the agitation intensifies, their behavior appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated. Agitation episodes are currently most often treated with antipsychotics and / or benzodiazepines in oral or intramuscular injection preparations. However, there are no non-invasive therapies that work within 30 minutes to help agitated patients in need of treatment.

About ADASUVE (Staccato loxapine) and the Staccato System

ADASUVE is an anti-agitation product candidate that combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. Click here to see an animation of how the Staccato system works. In clinical studies, ADASUVE has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The ADASUVE NDA contains efficacy and safety data from more than 1,600 patients and subjects who have been studied in thirteen different clinical trials.

Read the full article here: http://www.marketwatch.com/story/alexza-announces-adasuvetm-staccato-loxapine-pdufa-goal-date-of-february-4-2012-2011-08-19?reflink=MW_news_stmpb

I like the concept here. I don’t react well to any kind of anti-psychotic, conventional or atypical, but I find it really gratifying just to know that researchers are thinking out of the box in any capacity when treating mental health – or any health – issues.

I’m extremely impressed with your writing skills as well as with the layout on your blog. Is this a paid theme or did you modify it yourself? Anyway keep up the excellent quality writing, it’s rare to see a great blog like this one these days..

Hi, Katlyn. I am so sorry – the spam filter caught your comment and I didn’t see it until this morning. Thanks so much for letting me know you enjoy the blog and the writing. It means a lot. I use the twenty-ten theme and it’s free (if you search for it you’ll have to spell it out the number.). Let me know if you start a blog…I’d love to check it out. Take care!

3 Comments

Leave a Reply

Abilify
3
Abilify in Court – July 2017 Update

It’s been five years since I wrote, Success! I’ve Quit Abilify.  Since then, the post has received over 3500 views.  And all told, views for posts (linked below) related to the BS I endured while taking Abilify total over 49,000. The struggle is real. I haven’t posted for over a …

Bipolar
8
Polypharmacy and Bipolar Disorder

How many meds do you use to treat your bipolar disorder?  And your co-morbid afflictions?  Personally, I get off easy and take only four. In the treatment of bipolar disorder, polypharmacy (the use of multiple meds to treat a disease or disorder) is the norm.  And generally, bipolar I patients …

Bipolar
5
Heritable bipolar phenotypes pinned down

(I don’t usually quote an entire article, but this subject is near and dear to my heart….) Heritable bipolar phenotypes p inned down Published on February 14, 2014 at 5:12 PM By Eleanor McDermid, Senior medwireNews Reporter   A large study has pinpointed brain and behavioural traits that are genetically influenced and …

error: Content is protected !!